Natera: Diagnostic Specialist Grows 38% in Q2 - Price Jump to New All-Time High

Natera is a diagnostics company specializing in cell-free DNA tests in the areas of oncology, women's health, and organ transplantation. Clinical oncology tests increased by 57.2% in the most recent quarter. Reimbursements and approvals in Japan are acting as drivers. In Q2, revenue was increased by $37.7 million. The revenue forecast for 2026 has been raised to 31%.   The stock of Natera (NTRA) has already gained 132% within the last 12 months and reached a new all-time high of $323.01 on August 7, with a price jump of over 21%...